Equities Analysts Offer Predictions for CNTB Q1 Earnings

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Connect Biopharma in a research note issued on Wednesday, April 8th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of ($0.24) per share for the quarter. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.71) EPS, FY2029 earnings at ($0.42) EPS and FY2030 earnings at $0.02 EPS.

Connect Biopharma (NASDAQ:CNTB) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. The business had revenue of ($0.05) million during the quarter, compared to analyst estimates of $0.00 million.

CNTB has been the subject of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Connect Biopharma in a research report on Wednesday, January 21st. BTIG Research restated a “buy” rating and set a $10.00 target price on shares of Connect Biopharma in a research report on Tuesday, March 31st. Finally, Wall Street Zen upgraded Connect Biopharma to a “hold” rating in a research report on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Connect Biopharma has an average rating of “Moderate Buy” and an average target price of $8.67.

Connect Biopharma Price Performance

Connect Biopharma stock opened at $2.82 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 3.74. The firm has a market cap of $159.39 million, a P/E ratio of -2.82 and a beta of -0.21. The business’s fifty day moving average is $2.74 and its two-hundred day moving average is $2.37. Connect Biopharma has a 52 week low of $0.61 and a 52 week high of $3.82.

Hedge Funds Weigh In On Connect Biopharma

Several hedge funds have recently added to or reduced their stakes in the stock. HRT Financial LP lifted its stake in Connect Biopharma by 60.5% in the fourth quarter. HRT Financial LP now owns 16,785 shares of the company’s stock valued at $47,000 after buying an additional 6,328 shares during the period. SmartHarvest Portfolios LLC acquired a new position in Connect Biopharma in the fourth quarter valued at about $36,000. Persistent Asset Partners Ltd acquired a new position in Connect Biopharma in the fourth quarter valued at about $76,000. XTX Topco Ltd acquired a new position in Connect Biopharma in the second quarter valued at about $29,000. Finally, Royal Bank of Canada acquired a new position in Connect Biopharma in the fourth quarter valued at about $114,000. Institutional investors and hedge funds own 58.72% of the company’s stock.

Insiders Place Their Bets

In related news, Director James Huang bought 1,160,000 shares of the business’s stock in a transaction on Tuesday, March 31st. The shares were purchased at an average price of $3.45 per share, with a total value of $4,002,000.00. Following the completion of the purchase, the director owned 13,160,000 shares of the company’s stock, valued at $45,402,000. This represents a 9.67% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 22.60% of the company’s stock.

Key Headlines Impacting Connect Biopharma

Here are the key news stories impacting Connect Biopharma this week:

• Positive Sentiment: HC Wainwright raised several multi-year EPS targets and improved downside forecasts — including upgrading FY2030 to $0.02 from a prior ($0.11) estimate — signaling a more constructive long-term outlook for CNTB. HC Wainwright coverage at MarketBeat
• Neutral Sentiment: The analyst also published detailed quarterly forecasts for 2026 (Q1–Q4 EPS roughly ($0.24)–($0.26)), giving investors clearer near-term expectations but no immediate revenue upside in the projections. These estimates provide guidance for modeling cash needs and dilution timing. HC Wainwright coverage at MarketBeat
• Negative Sentiment: Despite upward revisions, HC Wainwright still forecasts a sizable FY2026 loss (now ($0.98) per share), which keeps near-term fundamentals weak and could limit upside until clinical or commercial catalysts materialize. Investors focused on cash burn, funding needs or near-term dilution should factor this in. HC Wainwright coverage at MarketBeat
• Neutral Sentiment: Broader analyst commentary including Connect Biopharma was also featured in a market roundup published by The Globe and Mail — useful for context but not a primary catalyst. Analysts Offer Insights on Healthcare Companies

About Connect Biopharma

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.